ArticlePhysics and imaging in radiation oncology2025
Comparison of interstitial high-dose-rate brachytherapy and stereotactic radiotherapy in breath-hold technique for inoperable primary and secondary liver tumors.
Article in Physics and imaging in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Role of High-Dose-Rate Brachytherapy (Interventional Radiotherapy) in the Reirradiation of Liver Metastases.Cancers · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: In recent years, ablative radiotherapy of primary and secondary liver tumors has become a highly regarded treatment option. We aimed to compare high-dose-rate interstitial brachytherapy (HDR-iBT) and stereotactic body radiotherapy (SBRT) in free breathing (FB) and deep inspiration breath hold (DIBH) in order to support future decisions on the appropriate radiation technique for liver tumors. Materials and methods: Forty-two patients with 1-4 liver malignancies undergoing HDR-iBT with 1x15-20 Gy were included. Eighty-eight SBRT plans in DIBH or FB with a prescription dose of 3x12.5 Gy to the surrounding 67 % isodose were generated using the HDR-iBT-computed tomography. Dose-volume parameters according to ICRU91 regarding organs-at-risk (OAR), target coverage, generalized equivalent uniform dose (gEUD Results: The mean target doses for HDR-iBT were at least twice as high as in SBRT, but target coverage was significantly more conformal for SBRT and the gEUD Conclusion: While SBRT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.